BML Investment Partners, L.P. 13D and 13G filings for AN2 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-06-18 11:08 am Sale | 2025-06-17 | 13D | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 427,432 1.400% | -2,789,991 (-86.72%) | Filing |
| 2025-05-30 5:46 pm Sale | 2025-05-28 | 13D | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 3,217,423 10.700% | -2,532,009 (-44.04%) | Filing |
| 2025-05-07 10:27 am Unchanged | 2025-05-07 | 13D | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 5,749,432 19.100% | 0 (Unchanged) | Filing |
| 2025-02-13 4:28 pm Unchanged | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 5,749,432 19.200% | 0 (Unchanged) | Filing |
| 2024-08-14 9:00 pm Purchase | 2024-08-14 | 13G | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 5,749,432 19.300% | 1,500,000 (+35.30%) | Filing |
| 2024-08-12 4:48 pm Purchase | 2024-08-09 | 13G | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 4,249,432 14.200% | 4,249,432 (New Position) | Filing |